The FDA granted priority review status to Genzyme’s experimental, all-oral Gaucher’s disease treatment Cerdelga (eliglustat).
The FDA’s priority label means the regulator will decide for or against the twice-a-day pill within six months.
The Sanofi subsidiary said in a statement that the 400-patient clinical trial supporting the filing is the largest ever conducted for Gaucher’s disease.
